Natural recurring desire for food. Alterations may be induced by APPETITE DEPRESSANTS or APPETITE STIMULANTS.
Physiologic mechanisms which regulate or control the appetite and food intake.
Agents that are used to suppress appetite.
Agents that are used to stimulate appetite. These drugs are frequently used to treat anorexia associated with cancer and AIDS.
Full gratification of a need or desire followed by a state of relative insensitivity to that particular need or desire.
The desire for FOOD generated by a sensation arising from the lack of food in the STOMACH.
Behavioral response associated with the achieving of gratification.
A 28-amino acid, acylated, orexigenic peptide that is a ligand for GROWTH HORMONE SECRETAGOGUE RECEPTORS. Ghrelin is widely expressed but primarily in the stomach in the adults. Ghrelin acts centrally to stimulate growth hormone secretion and food intake, and peripherally to regulate energy homeostasis. Its large precursor protein, known as appetite-regulating hormone or motilin-related peptide, contains ghrelin and obestatin.
The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
The consumption of edible substances.
A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion.
Behavioral responses or sequences associated with eating including modes of feeding, rhythmic patterns of eating, and time intervals.
The consumption of liquids.
Total number of calories taken in daily whether ingested or by parenteral routes.
A drive stemming from a physiological need for WATER.
Hormones synthesized from amino acids. They are distinguished from INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS in that their actions are systemic.
A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage.
A portion of the food eaten for the day, usually at regular occasions during the day.
Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE.
A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release.
HORMONES secreted by the gastrointestinal mucosa that affect the timing or the quality of secretion of digestive enzymes, and regulate the motor activity of the digestive system organs.
A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.
Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed)
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
The chemical reactions involved in the production and utilization of various forms of energy in cells.
The time frame after a meal or FOOD INTAKE.
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
A status with BODY WEIGHT that is grossly above the acceptable or desirable weight, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
The selection of one food over another.
General ill health, malnutrition, and weight loss, usually associated with chronic disease.
Megestrol acetate is a progestogen with actions and uses similar to those of the progestogens in general. It also has anti-androgenic properties. It is given by mouth in the palliative treatment or as an adjunct to other therapy in endometrial carcinoma and in breast cancer. Megestrol acetate has been approved to treat anorexia and cachexia. (From Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1995)
A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.
Behaviors associated with the ingesting of water and other liquids; includes rhythmic patterns of drinking (time intervals - onset and duration), frequency and satiety.
A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
The evacuation of food from the stomach into the duodenum.
Injections into the cerebral ventricles.
A secreted protein of approximately 131 amino acids that is related to AGOUTI SIGNALING PROTEIN and is also an antagonist of MELANOCORTIN RECEPTOR activity. It is expressed primarily in the HYPOTHALAMUS and the ADRENAL GLAND. As a paracrine signaling molecule, AGRP is known to regulate food intake and body weight. Elevated AGRP has been associated with OBESITY.
The ability to detect chemicals through gustatory receptors in the mouth, including those on the TONGUE; the PALATE; the PHARYNX; and the EPIGLOTTIS.
Ingestion of a greater than optimal quantity of food.
Sodium or sodium compounds used in foods or as a food. The most frequently used compounds are sodium chloride or sodium glutamate.
A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.
A 30-kDa protein synthesized primarily in the ANTERIOR PITUITARY GLAND and the HYPOTHALAMUS. It is also found in the skin and other peripheral tissues. Depending on species and tissues, POMC is cleaved by PROHORMONE CONVERTASES yielding various active peptides including ACTH; BETA-LIPOTROPIN; ENDORPHINS; MELANOCYTE-STIMULATING HORMONES; and others (GAMMA-LPH; CORTICOTROPIN-LIKE INTERMEDIATE LOBE PEPTIDE; N-terminal peptide of POMC or NPP).
Any substances taken in by the body that provide nourishment.
Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the U.S. and in other countries.
Decrease in existing BODY WEIGHT.
Glucose in blood.
Increase in BODY WEIGHT over existing weight.
A melanocortin receptor subtype found primarily in BRAIN. It shows specificity for ALPHA-MSH; BETA-MSH and ADRENOCORTICOTROPIC HORMONE.
Carbohydrates present in food comprising digestible sugars and starches and indigestible cellulose and other dietary fibers. The former are the major source of energy. The sugars are in beet and cane sugar, fruits, honey, sweet corn, corn syrup, milk and milk products, etc.; the starches are in cereal grains, legumes (FABACEAE), tubers, etc. (From Claudio & Lagua, Nutrition and Diet Therapy Dictionary, 3d ed, p32, p277)
Transmembrane proteins that recognize and bind GHRELIN, a potent stimulator of GROWTH HORMONE secretion and food intake in mammals. Ghrelin receptors are found in the pituitary and HYPOTHALAMUS. They belong to the family of G-PROTEIN-COUPLED RECEPTORS.
The region of the STOMACH at the junction with the DUODENUM. It is marked by the thickening of circular muscle layers forming the pyloric sphincter to control the opening and closure of the lumen.
A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1).
A group of disorders characterized by physiological and psychological disturbances in appetite or food intake.
State of the body in relation to the consumption and utilization of nutrients.

A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. (1/863)

The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P<0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P<0.05). The combination of megestrol acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted.  (+info)

Effect of postweaning feeding on the performance and energy balance of female rabbits at different physiological states. (2/863)

The feeding of a high-fiber and low-energy diet to young rabbit does from weaning to the first kindling was used to modify their body reserves, stimulate their energy intake, and reduce the energy deficit during the first lactation. Rabbits (53 per group) were given ad libitum access to either a control or high-fiber diet (CP, 17.6 vs 15.8% of DM; crude fiber, 15.5 vs 19.9% of DM; digestible energy, 2,565 vs 2,261 kcal/kg of DM, respectively) from weaning to their first kindling. During lactation, both groups received the same diet, which contained 19.3% CP, 16.5% crude fiber, and 2,634 kcal/kg digestible energy (dry matter basis). Four comparative slaughters were performed to estimate the chemical and energy balance of rabbit does at different physiological states: at the beginning of the trial (12 rabbits, 45 d of age), at mating (10 rabbits per group, 136 d), at kindling (10 rabbits per group, 167 d), and at the end of lactation (12 and 11 rabbits for the control and the high-fiber group, 197 d). Large changes in body weight and composition were observed between slaughters. From 45 d to mating, doe body fat and energy increased 7.93 and 4.64 times the initial content, respectively. During pregnancy, body protein concentration decreased from 203 to 186 g/kg. At the end of lactation, body fat and energy concentration were reduced to values close to those measured at 45 d of age. Dietary treatment affected body chemical and energy balance during pregnancy and lactation but not reproductive and lactational performance. The high-fiber diet stimulated feed intake from weaning to the first kindling but not dietary energy intake. During lactation, the rabbits fed the high-fiber diet ate 10 kcal x d(-1) x kg live weight(-.75) more and lost less body fat (-405 vs -504 g) and body energy (-3,628 vs -4,294 kcal) than the does fed the control diet (P < .001). In the same period, all does showed water and protein retention (185 and 45 g, on average) regardless of dietary treatment. In conclusion, feeding young does a high-fiber diet until their first kindling reduced the chemical and energy body deficit at the end of the first lactation.  (+info)

Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility. (3/863)

BACKGROUND: Aging is associated with a decrease in appetite and a slowing of gastric emptying. The gastrointestinal hormones cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1), and peptide YY (PYY) may mediate these changes. OBJECTIVE: We investigated whether aging influenced the secretion of CCK, GLP-1, and PYY and their effects on appetite and pyloric motility. DESIGN: Eight healthy older (65-80 y) and 7 younger (20-34 y) men received isoenergetic (12.1 kJ/min) intraduodenal infusions of lipid and glucose for 120 min on separate days. Plasma CCK, GLP-1, and PYY concentrations were measured. RESULTS: Plasma CCK concentrations were higher in older than in younger subjects (P = 0.004) as a result of higher baseline values (4.7+/-0.2 compared with 3.2+/-0.2 pmol/L; P < 0.0001) and a greater rise during lipid infusion (increase from baseline: 7.1+/-0.5 compared with 5.3+/-0.6 pmol/L; P = 0.048). Plasma GLP-1 and PYY concentrations were not significantly different between groups. The decrease in hunger during intraduodenal lipid infusion was inversely related to the increase in CCK, GLP-1, and PYY in younger but not older subjects. During intraduodenal lipid infusion, the increase in isolated pyloric pressure wave (IPPW) frequency was positively related to GLP-1 and PYY and the increase in IPPW amplitude was positively related to CCK in older but not younger subjects, whereas the increase in IPPW amplitude and pyloric tone was negatively related to GLP-1 and PYY in younger subjects. CONCLUSIONS: Human aging is associated with increased CCK concentrations, which may contribute to the slowing of gastric emptying, mediated by increased pyloric motility. The role of increased plasma CCK concentrations in mediating the age-related decrease in appetite remains to be established.  (+info)

Sodium depletion and aldosterone decrease dopamine transporter activity in nucleus accumbens but not striatum. (4/863)

Motivated behaviors, including sodium (Na) appetite, are correlated with increased dopamine (DA) transmission in the nucleus accumbens (NAc). DA transporter (DAT) modulation affects DA transmission and may play a role in motivated behaviors. In vivo Na depletion, which reliably induces Na appetite, was correlated with robust decreases in DA uptake via the DAT in the rat NAc with rotating disk electrode voltammetry [1,277 +/- 162 vs. 575 +/- 89 pmol. s-1. g-1; Vmax of transport for control vs. Na-depleted tissue]. Plasma aldosterone (Aldo) levels increase after in vivo Na depletion and contribute to Na appetite. Decreased DAT activity in the NAc was observed after in vitro Aldo treatment (428 +/- 28 vs. 300 +/- 25 pmol. s-1. g-1). Neither treatment affected DAT activity in the striatum. These results suggest that a direct action of Aldo is one possible mechanism by which Na depletion induces a reduction in DAT activity in the NAc. Reduced DAT activity may play a role in generating increased NAc DA transmission during Na appetite, which may underlie the motivating properties of Na for the Na-depleted rat.  (+info)

Roles of aldosterone and angiotensin in maturation of sodium appetite in furosemide-treated rats. (5/863)

When rats are treated with furosemide, there is a rapid natriuresis. However, increased sodium appetite does not occur until some time later. One hypothesis to explain this delay is that increased circulating levels of the hormones of sodium depletion prime or sensitize the brain circuits involved in sodium appetite, perhaps by induction of target gene(s). In the present study, we describe the time course of the temporal maturation of sodium appetite after furosemide treatment and the associated changes in plasma levels of ANG II and aldosterone and in plasma volume. Sodium appetite is modest 3 h after furosemide treatment, is increased after 12 h, and is still larger after 24 h. This pattern is evident with repeated testing. Plasma levels of aldosterone and plasma renin activity are substantially increased 3 h after furosemide treatment, and so the NaCl appetite cannot result simply from progressively increasing levels of these hormones. Furthermore, activation of the subfornical organ and the ventral lamina terminalis, assessed with c-Fos immunocytochemistry, did not differ across these three times. Metyrapone, an inhibitor of adrenal steroid synthesis, was used to examine sodium appetite in the absence of elevations in aldosterone after furosemide treatment. Although metyrapone effectively blocked the increase in aldosterone, it was without effect on the appetite 3 or 24 h after furosemide treatment. Furthermore, elevations of plasma aldosterone by the use of minipumps for several days before furosemide treatment did not prime or potentiate but instead tended to inhibit the induced sodium appetite, despite achieving levels of aldosterone and plasma renin activity typically associated with a robust sodium appetite. Infusions of DOCA gave a similar result. Lastly, minipump infusions of ANG II also did not potentiate sodium appetite. Thus neither addition nor subtraction of these hormones alone influenced sodium appetite under these conditions.  (+info)

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. (6/863)

Glucagon-like peptide-1-(7-36) amide (GLP-1) is an incretin hormone of the enteroinsular axis. Recent experimental evidence in animals and healthy subjects suggests that GLP-1 has a role in controlling appetite and energy intake in humans. We have therefore examined in a double-blind, placebo-controlled, crossover study in 12 patients with diabetes type 2 the effect of intravenously infused GLP-1 on appetite sensations and energy intake. On 2 days, either saline or GLP-1 (1.5 pmol. kg-1. min-1) was given throughout the experiment. Visual analog scales were used to assess appetite sensations; furthermore, food and fluid intake of a test meal were recorded, and blood was sampled for analysis of plasma glucose and hormone levels. GLP-1 infusion enhanced satiety and fullness compared with placebo (P = 0.028 for fullness and P = 0.026 for hunger feelings). Energy intake was reduced by 27% by GLP-1 (P = 0.034) compared with saline. The results demonstrate a marked effect of GLP-1 on appetite by showing enhanced satiety and reduced energy intake in patients with diabetes type 2.  (+info)

Neuropeptide Y restores appetite and alters concentrations of GH after central administration to endotoxic sheep. (7/863)

The objective of this study was to determine whether neuropeptide Y (NPY) and recombinant human interleukin-1 receptor antagonist (IL-1ra) would: first, increase food intake; secondly, decrease concentrations of GH; thirdly, reduce GHRH-induced release of GH; and fourthly, reduce changes to concentrations of IGF-I in plasma during experimental endotoxemia in sheep. Six treatments were given to six castrated male sheep in a 6x6 Latin square treatment order. Osmotic mini-pumps were implanted at 0 h and a jugular vein was cannulated. Each sheep was continuously infused with saline (0.9%) or lipopolysaccharide (LPS) (20 micrograms/kg per 24 h, s.c.) at 10 microliters/h for 72 h via the osmotic mini-pumps. Blood samples (3 ml) were collected at 15-min intervals from 24 to 33 h. At 26 h, one of three treatments (artificial cerebrospinal fluid, NPY or IL-1ra) was injected i.c.v. within 30 s (0.3 microgram/kg), then infused i.c.v. from 26 to 33 h (600 microliters/h) at 0.3 microgram/kg per h. GHRH was injected i.v. (0.075 microgram/kg) at 32 h after which blood samples were collected at 5, 10, 15, 30, 45 and 60 min. Feed intake was reduced up to 50% for 48 h in LPS-treated compared with non-LPS-treated sheep. NPY restored feed intake in LPS-treated sheep and induced hyperphagia in non-LPS-treated sheep from 24 to 48 h. In contrast, IL-1ra did not affect appetite. Injection of NPY increased concentrations of GH from 26 to 27 h, while IL-1ra had no effect. Infusion of NPY suppressed GHRH-induced release of GH. However, no treatment altered pulse secretion parameters of GH. Concentrations of IGF-I were 20% higher at 72 h in LPS-treated sheep given NPY than in sheep treated with LPS alone, and this may reflect increased appetite from 24 to 48 h. We concluded that reduced appetite during endotoxemia is due to down-regulation of an NPY-mediated mechanism. Furthermore, NPY stimulates release of GH in healthy sheep, does not reduce pulse secretion parameters of GH, but does suppress GHRH-induced release of GH in endotoxic sheep. Therefore, NPY may be an important neurotransmitter linking appetite with regulation of GH during endotoxemic and healthy states in sheep.  (+info)

Influences of long-term administration of 24R, 25-dihydroxyvitamin D3, a vitamin D3 derivative, in rats. (8/863)

In order to examine the influences by long-term feeding of 24R, 25 dihydroxyvitamin D3[24R, 25(OH)2D3], an active form of vitamin D, Wistar rats (14-week-old, male, 20 rats/group) were fed a powder diet containing 0 or 5 ppm 24R, 25(OH)2D3 for 57 weeks. Final body weights and total food consumption were comparable between the groups. Urinary calcium levels were significantly (p < 0.05 or 0.01) increased by the administration of 24R, 25(OH)2D3 at weeks 3, 22 and 56, although the levels of serum calcium did not differ between the groups at the termination of week 57. In the 24R, 25(OH)2D3 group, weights of the adrenals and femurs were significantly (p < 0.01) increased. Histopathologically, this was found due to thickening of cortical bone in the femurs, and medullary hyperplasia and pheochromocytoma of the adrenals. Immunohistochemically, proliferating cell nuclear antigen (PCNA)-labeling indices for intact adrenal medulla, medullary hyperplasia and pheochromocytoma in the 24R, 25(OH)2D3 group were respectively 1.82 +/- 1.21, 5.88 +/- 4.13 and 16, all higher than that for the adrenal medulla in the control group (0.87 +/- 0.67). These results indicate that 24R, 25(OH)2D3 at a dose with which serum calcium is not chronically increased causes thickening of the cortex of the femur, and development of adrenal proliferative lesions, suggesting that rats may be too sensitive for results to be relevant to human risk assessment.  (+info)

Appetite is the desire to eat or drink something, which is often driven by feelings of hunger or thirst. It is a complex process that involves both physiological and psychological factors. Physiologically, appetite is influenced by the body's need for energy and nutrients, as well as various hormones and neurotransmitters that regulate hunger and satiety signals in the brain. Psychologically, appetite can be affected by emotions, mood, stress levels, and social factors such as the sight or smell of food.

In medical terms, a loss of appetite is often referred to as anorexia, which can be caused by various factors such as illness, medication, infection, or psychological conditions like depression. On the other hand, an excessive or abnormal appetite is known as polyphagia and can be a symptom of certain medical conditions such as diabetes or hyperthyroidism.

It's important to note that while "anorexia" is a medical term used to describe loss of appetite, it should not be confused with the eating disorder anorexia nervosa, which is a serious mental health condition characterized by restrictive eating, distorted body image, and fear of gaining weight.

Appetite regulation refers to the physiological and psychological processes that control and influence the desire to eat food. This complex system involves a variety of hormones, neurotransmitters, and neural pathways that work together to help maintain energy balance and regulate body weight. The hypothalamus in the brain plays a key role in appetite regulation by integrating signals from the digestive system, fat cells, and other organs to adjust feelings of hunger and fullness.

The hormones leptin and ghrelin are also important regulators of appetite. Leptin is released from fat cells and acts on the hypothalamus to suppress appetite and promote weight loss, while ghrelin is produced in the stomach and stimulates appetite and promotes weight gain. Other factors that can influence appetite regulation include stress, emotions, sleep patterns, and cultural influences.

Abnormalities in appetite regulation can contribute to the development of eating disorders such as anorexia nervosa, bulimia nervosa, and binge eating disorder, as well as obesity and other health problems. Understanding the mechanisms of appetite regulation is an important area of research for developing effective treatments for these conditions.

Appetite depressants are medications or substances that reduce or suppress feelings of hunger and appetite. They can be prescribed to treat various medical conditions, such as obesity or binge eating disorder, where weight loss is a recommended treatment goal. Some common appetite depressants include:

1. Phentermine: This medication works by stimulating the release of certain neurotransmitters in the brain that help suppress appetite and increase metabolism. It is often prescribed for short-term use (up to 12 weeks) as part of a comprehensive weight loss plan.

2. Diethylpropion: Similar to phentermine, diethylpropion stimulates the release of neurotransmitters that suppress appetite and increase metabolism. It is also prescribed for short-term use in treating obesity.

3. Naltrexone-bupropion (Contrave): This combination medication helps manage weight by reducing appetite and increasing feelings of fullness. Naltrexone is an opioid antagonist that blocks the rewarding effects of food, while bupropion is an antidepressant that can help reduce cravings for high-calorie foods.

4. Lorcaserin (Belviq): This medication works by selectively activating serotonin receptors in the brain, which helps promote satiety and reduce appetite. It was withdrawn from the US market in 2020 due to concerns about its potential link to an increased risk of cancer.

5. Topiramate (Topamax): Although primarily used as an anticonvulsant, topiramate has also been found to have appetite-suppressing effects. It is often combined with phentermine in a single formulation (Qsymia) for the treatment of obesity.

6. Cannabis: Some studies suggest that cannabinoids, the active compounds in marijuana, may help reduce hunger and promote weight loss by interacting with the endocannabinoid system in the body. However, more research is needed to fully understand its potential as an appetite depressant.

It's important to note that appetite suppressants should only be used under the guidance of a healthcare professional and as part of a comprehensive weight management plan. These medications can have side effects and potential risks, so it's crucial to discuss their use with your doctor before starting any new treatment regimen.

Appetite stimulants are medications or substances that increase the desire to eat or improve appetite. They work by affecting brain chemicals, hormones, or other systems involved in regulating hunger and fullness. Some commonly used appetite stimulants include:

1. Megestrol acetate: a synthetic progestin hormone that is often prescribed for cancer-related weight loss and anorexia. It works by stimulating appetite and promoting weight gain.
2. Dronabinol: a synthetic form of THC, the active ingredient in marijuana. It is approved for treating AIDS-related anorexia and chemotherapy-induced nausea and vomiting. Dronabinol can increase appetite and promote weight gain.
3. Corticosteroids: medications that mimic the effects of hormones produced by the adrenal gland. They can help improve appetite, but their long-term use is associated with significant side effects.
4. Cyproheptadine: an antihistamine medication that can also stimulate appetite. It is sometimes used off-label to treat appetite loss in various conditions, such as cancer or HIV/AIDS.
5. Ghrelin agonists: these are medications that mimic the effects of ghrelin, a hormone produced by the stomach that increases hunger and appetite. Currently, there are no FDA-approved ghrelin agonists for appetite stimulation, but research is ongoing.

It's important to note that while appetite stimulants can help improve food intake in some individuals, they may not be effective for everyone, and their use should be carefully monitored due to potential side effects and interactions with other medications. Always consult a healthcare professional before starting any new medication or supplement.

Satiation is a term used in the field of nutrition and physiology, which refers to the feeling of fullness or satisfaction that one experiences after eating food. It is the point at which further consumption of food no longer adds to the sensation of hunger or the desire to eat. This response is influenced by various factors such as the type and amount of food consumed, nutrient composition, energy density, individual appetite regulatory hormones, and gastric distension.

Satiation plays a crucial role in regulating food intake and maintaining energy balance. Understanding the mechanisms underlying satiation can help individuals make healthier food choices and prevent overeating, thereby reducing the risk of obesity and other related health issues.

In medical terms, "hunger" is not specifically defined as a clinical condition. However, it generally refers to the physiological need or desire for food and calories, driven by mechanisms in the brain and body that regulate energy balance. This sensation often arises when the body's energy stores are depleted, or when there has been a prolonged period without food intake.

Hunger is primarily mediated by hormones such as ghrelin, which stimulates appetite, and leptin, which signals satiety. The hypothalamus in the brain plays a crucial role in integrating these hormonal signals to regulate hunger and energy balance. Additionally, other factors like sleep deprivation, stress, and certain medical conditions can also influence feelings of hunger.

Satiety response is a term used in the field of nutrition and physiology to describe the feeling of fullness or satisfaction that follows food consumption. It is a complex process regulated by several factors, including the mechanical and chemical signals generated during digestion, hormonal responses, and psychological factors. The satiety response helps control food intake and energy balance by inhibiting further eating until the body has had enough time to metabolize and absorb the nutrients from the meal.

The satiety response can be influenced by various factors such as the type, volume, and texture of food consumed, as well as individual differences in appetite regulation and metabolism. Understanding the mechanisms underlying the satiety response is important for developing strategies to promote healthy eating behaviors and prevent overeating, which can contribute to obesity and other health problems.

Ghrelin is a hormone primarily produced and released by the stomach with some production in the small intestine, pancreas, and brain. It is often referred to as the "hunger hormone" because it stimulates appetite, promotes food intake, and contributes to the regulation of energy balance.

Ghrelin levels increase before meals and decrease after eating. In addition to its role in regulating appetite and meal initiation, ghrelin also has other functions, such as modulating glucose metabolism, insulin secretion, gastric motility, and cardiovascular function. Its receptor, the growth hormone secretagogue receptor (GHS-R), is found in various tissues throughout the body, indicating its wide range of physiological roles.

Anorexia is a medical condition defined as a loss of appetite or aversion to food, leading to significant weight loss. It can be a symptom of various underlying causes, such as mental health disorders (most commonly an eating disorder called anorexia nervosa), gastrointestinal issues, cancer, infections, or side effects of medication. In this definition, we are primarily referring to anorexia as a symptom rather than the specific eating disorder anorexia nervosa.

Anorexia nervosa is a psychological eating disorder characterized by:

1. Restriction of energy intake leading to significantly low body weight (in context of age, sex, developmental trajectory, and physical health)
2. Intense fear of gaining weight or becoming fat, or persistent behavior that interferes with weight gain
3. Disturbed body image, such as overvaluation of self-worth regarding shape or weight, or denial of the seriousness of low body weight

Anorexia nervosa has two subtypes: restricting type and binge eating/purging type. The restricting type involves limiting food intake without engaging in binge eating or purging behaviors (such as self-induced vomiting or misuse of laxatives, diuretics, or enemas). In contrast, the binge eating/purging type includes recurrent episodes of binge eating and compensatory behaviors to prevent weight gain.

It is essential to differentiate between anorexia as a symptom and anorexia nervosa as a distinct psychological disorder when discussing medical definitions.

The medical definition of "eating" refers to the process of consuming and ingesting food or nutrients into the body. This process typically involves several steps, including:

1. Food preparation: This may involve cleaning, chopping, cooking, or combining ingredients to make them ready for consumption.
2. Ingestion: The act of taking food or nutrients into the mouth and swallowing it.
3. Digestion: Once food is ingested, it travels down the esophagus and enters the stomach, where it is broken down by enzymes and acids to facilitate absorption of nutrients.
4. Absorption: Nutrients are absorbed through the walls of the small intestine and transported to cells throughout the body for use as energy or building blocks for growth and repair.
5. Elimination: Undigested food and waste products are eliminated from the body through the large intestine (colon) and rectum.

Eating is an essential function that provides the body with the nutrients it needs to maintain health, grow, and repair itself. Disorders of eating, such as anorexia nervosa or bulimia nervosa, can have serious consequences for physical and mental health.

Peptide YY (PYY) is a small peptide hormone consisting of 36 amino acids, that is released by the L cells in the intestinal epithelium in response to feeding. It is a member of the neuropeptide Y (NPY) family and plays a crucial role in regulating appetite and energy balance.

After eating, PYY is released into the circulation and acts on specific receptors in the hypothalamus to inhibit food intake. This anorexigenic effect of PYY is mediated by its ability to decrease gastric emptying, reduce intestinal motility, and increase satiety.

PYY has also been shown to have effects on glucose homeostasis, insulin secretion, and inflammation, making it a potential therapeutic target for the treatment of obesity, diabetes, and other metabolic disorders.

Feeding behavior refers to the various actions and mechanisms involved in the intake of food and nutrition for the purpose of sustaining life, growth, and health. This complex process encompasses a coordinated series of activities, including:

1. Food selection: The identification, pursuit, and acquisition of appropriate food sources based on sensory cues (smell, taste, appearance) and individual preferences.
2. Preparation: The manipulation and processing of food to make it suitable for consumption, such as chewing, grinding, or chopping.
3. Ingestion: The act of transferring food from the oral cavity into the digestive system through swallowing.
4. Digestion: The mechanical and chemical breakdown of food within the gastrointestinal tract to facilitate nutrient absorption and eliminate waste products.
5. Assimilation: The uptake and utilization of absorbed nutrients by cells and tissues for energy production, growth, repair, and maintenance.
6. Elimination: The removal of undigested material and waste products from the body through defecation.

Feeding behavior is regulated by a complex interplay between neural, hormonal, and psychological factors that help maintain energy balance and ensure adequate nutrient intake. Disruptions in feeding behavior can lead to various medical conditions, such as malnutrition, obesity, eating disorders, and gastrointestinal motility disorders.

The term "drinking" is commonly used to refer to the consumption of beverages, but in a medical context, it usually refers to the consumption of alcoholic drinks. According to the Merriam-Webster Medical Dictionary, "drinking" is defined as:

1. The act or habit of swallowing liquid (such as water, juice, or alcohol)
2. The ingestion of alcoholic beverages

It's important to note that while moderate drinking may not pose significant health risks for some individuals, excessive or binge drinking can lead to a range of negative health consequences, including addiction, liver disease, heart disease, and increased risk of injury or violence.

"Energy intake" is a medical term that refers to the amount of energy or calories consumed through food and drink. It is an important concept in the study of nutrition, metabolism, and energy balance, and is often used in research and clinical settings to assess an individual's dietary habits and health status.

Energy intake is typically measured in kilocalories (kcal) or joules (J), with one kcal equivalent to approximately 4.184 J. The recommended daily energy intake varies depending on factors such as age, sex, weight, height, physical activity level, and overall health status.

It's important to note that excessive energy intake, particularly when combined with a sedentary lifestyle, can lead to weight gain and an increased risk of chronic diseases such as obesity, type 2 diabetes, and cardiovascular disease. On the other hand, inadequate energy intake can lead to malnutrition, decreased immune function, and other health problems. Therefore, it's essential to maintain a balanced energy intake that meets individual nutritional needs while promoting overall health and well-being.

Thirst, also known as dry mouth or polydipsia, is a physiological need or desire to drink fluids to maintain fluid balance and hydration in the body. It is primarily regulated by the hypothalamus in response to changes in osmolality and volume of bodily fluids, particularly blood. Thirst can be triggered by various factors such as dehydration, excessive sweating, diarrhea, vomiting, fever, burns, certain medications, and medical conditions affecting the kidneys, adrenal glands, or other organs. It is a vital homeostatic mechanism to ensure adequate hydration and proper functioning of various bodily systems.

Peptide hormones are a type of hormone consisting of short chains of amino acids known as peptides. They are produced and released by various endocrine glands and play crucial roles in regulating many physiological processes in the body, including growth and development, metabolism, stress response, and reproductive functions.

Peptide hormones exert their effects by binding to specific receptors on the surface of target cells, which triggers a series of intracellular signaling events that ultimately lead to changes in cell behavior or function. Some examples of peptide hormones include insulin, glucagon, growth hormone, prolactin, oxytocin, and vasopressin.

Peptide hormones are synthesized as larger precursor proteins called prohormones, which are cleaved by enzymes to release the active peptide hormone. They are water-soluble and cannot pass through the cell membrane, so they exert their effects through autocrine, paracrine, or endocrine mechanisms. Autocrine signaling occurs when a cell releases a hormone that binds to receptors on the same cell, while paracrine signaling involves the release of a hormone that acts on nearby cells. Endocrine signaling, on the other hand, involves the release of a hormone into the bloodstream, which then travels to distant target cells to exert its effects.

Diethylpropion is a sympathomimetic amine, which is a type of medication that stimulates the nervous system. It is primarily used as an appetite suppressant for the short-term treatment of obesity. Diethylpropion works by affecting the neurotransmitters in the brain that regulate appetite, leading to a decrease in food intake and an increase in weight loss.

Diethylpropion is available in immediate-release and extended-release forms, and it is typically taken two to three times a day, about one hour before meals. Common side effects of diethylpropion include dry mouth, constipation, difficulty sleeping, and increased heart rate. More serious side effects can include high blood pressure, irregular heartbeat, and seizures.

Diethylpropion is a controlled substance in many countries due to its potential for abuse and dependence. It should only be used under the close supervision of a healthcare provider and for a limited period of time.

Leptin is a hormone primarily produced and released by adipocytes, which are the fat cells in our body. It plays a crucial role in regulating energy balance and appetite by sending signals to the brain when the body has had enough food. This helps control body weight by suppressing hunger and increasing energy expenditure. Leptin also influences various metabolic processes, including glucose homeostasis, neuroendocrine function, and immune response. Defects in leptin signaling can lead to obesity and other metabolic disorders.

I'm sorry for any confusion, but "meals" is a term that refers to food or drink consumed at regular intervals as part of a person's daily diet, rather than a medical term. It is not typically defined in a medical context. However, in a nutritional or healthcare setting, meals are often discussed in terms of their timing, composition, and impact on factors such as medication administration, blood sugar control, and overall health.

The hypothalamus is a small, vital region of the brain that lies just below the thalamus and forms part of the limbic system. It plays a crucial role in many important functions including:

1. Regulation of body temperature, hunger, thirst, fatigue, sleep, and circadian rhythms.
2. Production and regulation of hormones through its connection with the pituitary gland (the hypophysis). It controls the release of various hormones by producing releasing and inhibiting factors that regulate the anterior pituitary's function.
3. Emotional responses, behavior, and memory formation through its connections with the limbic system structures like the amygdala and hippocampus.
4. Autonomic nervous system regulation, which controls involuntary physiological functions such as heart rate, blood pressure, and digestion.
5. Regulation of the immune system by interacting with the autonomic nervous system.

Damage to the hypothalamus can lead to various disorders like diabetes insipidus, growth hormone deficiency, altered temperature regulation, sleep disturbances, and emotional or behavioral changes.

Fenfluramine is a drug that was previously used for the short-term treatment of obesity. It works by suppressing appetite and increasing the feeling of fullness. Fenfluramine is an amphetamine derivative and stimulates the release of serotonin, a neurotransmitter in the brain that helps regulate mood, appetite, and sleep.

Fenfluramine was commonly prescribed in combination with phentermine, another appetite suppressant, under the brand name Fen-Phen. However, in 1997, the U.S. Food and Drug Administration (FDA) issued a public health warning about the potential risk of serious heart valve damage associated with the use of fenfluramine and withdrew its approval for the drug's use. Since then, fenfluramine has not been approved for medical use in many countries, including the United States.

Gastrointestinal (GI) hormones are a group of hormones that are secreted by cells in the gastrointestinal tract in response to food intake and digestion. They play crucial roles in regulating various physiological processes, including appetite regulation, gastric acid secretion, motility of the gastrointestinal tract, insulin secretion, and pancreatic enzyme release.

Examples of GI hormones include:

* Gastrin: Secreted by G cells in the stomach, gastrin stimulates the release of hydrochloric acid from parietal cells in the stomach lining.
* Ghrelin: Produced by the stomach, ghrelin is often referred to as the "hunger hormone" because it stimulates appetite and food intake.
* Cholecystokinin (CCK): Secreted by I cells in the small intestine, CCK promotes digestion by stimulating the release of pancreatic enzymes and bile from the liver. It also inhibits gastric emptying and reduces appetite.
* Gastric inhibitory peptide (GIP): Produced by K cells in the small intestine, GIP promotes insulin secretion and inhibits glucagon release.
* Secretin: Released by S cells in the small intestine, secretin stimulates the pancreas to produce bicarbonate-rich fluid that neutralizes stomach acid in the duodenum.
* Motilin: Secreted by MO cells in the small intestine, motilin promotes gastrointestinal motility and regulates the migrating motor complex (MMC), which is responsible for cleaning out the small intestine between meals.

These hormones work together to regulate digestion and maintain homeostasis in the body. Dysregulation of GI hormones can contribute to various gastrointestinal disorders, such as gastroparesis, irritable bowel syndrome (IBS), and diabetes.

Cholecystokinin (CCK) is a hormone that is produced in the duodenum (the first part of the small intestine) and in the brain. It is released into the bloodstream in response to food, particularly fatty foods, and plays several roles in the digestive process.

In the digestive system, CCK stimulates the contraction of the gallbladder, which releases bile into the small intestine to help digest fats. It also inhibits the release of acid from the stomach and slows down the movement of food through the intestines.

In the brain, CCK acts as a neurotransmitter and has been shown to have effects on appetite regulation, mood, and memory. It may play a role in the feeling of fullness or satiety after eating, and may also be involved in anxiety and panic disorders.

CCK is sometimes referred to as "gallbladder-stimulating hormone" or "pancreozymin," although these terms are less commonly used than "cholecystokinin."

A cross-over study is a type of experimental design in which participants receive two or more interventions in a specific order. After a washout period, each participant receives the opposite intervention(s). The primary advantage of this design is that it controls for individual variability by allowing each participant to act as their own control.

In medical research, cross-over studies are often used to compare the efficacy or safety of two treatments. For example, a researcher might conduct a cross-over study to compare the effectiveness of two different medications for treating high blood pressure. Half of the participants would be randomly assigned to receive one medication first and then switch to the other medication after a washout period. The other half of the participants would receive the opposite order of treatments.

Cross-over studies can provide valuable insights into the relative merits of different interventions, but they also have some limitations. For example, they may not be suitable for studying conditions that are chronic or irreversible, as it may not be possible to completely reverse the effects of the first intervention before administering the second one. Additionally, carryover effects from the first intervention can confound the results if they persist into the second treatment period.

Overall, cross-over studies are a useful tool in medical research when used appropriately and with careful consideration of their limitations.

Glucagon-like peptide 1 (GLP-1) is a hormone that is secreted by the intestines in response to food intake. It plays a crucial role in regulating blood sugar levels through several mechanisms, including stimulation of insulin secretion from the pancreas, inhibition of glucagon release, slowing gastric emptying, and promoting satiety. GLP-1 is an important target for the treatment of type 2 diabetes due to its insulin-secretory and glucose-lowering effects. In addition, GLP-1 receptor agonists are used in the management of obesity due to their ability to promote weight loss by reducing appetite and increasing feelings of fullness.

Energy metabolism is the process by which living organisms produce and consume energy to maintain life. It involves a series of chemical reactions that convert nutrients from food, such as carbohydrates, fats, and proteins, into energy in the form of adenosine triphosphate (ATP).

The process of energy metabolism can be divided into two main categories: catabolism and anabolism. Catabolism is the breakdown of nutrients to release energy, while anabolism is the synthesis of complex molecules from simpler ones using energy.

There are three main stages of energy metabolism: glycolysis, the citric acid cycle (also known as the Krebs cycle), and oxidative phosphorylation. Glycolysis occurs in the cytoplasm of the cell and involves the breakdown of glucose into pyruvate, producing a small amount of ATP and nicotinamide adenine dinucleotide (NADH). The citric acid cycle takes place in the mitochondria and involves the further breakdown of pyruvate to produce more ATP, NADH, and carbon dioxide. Oxidative phosphorylation is the final stage of energy metabolism and occurs in the inner mitochondrial membrane. It involves the transfer of electrons from NADH and other electron carriers to oxygen, which generates a proton gradient across the membrane. This gradient drives the synthesis of ATP, producing the majority of the cell's energy.

Overall, energy metabolism is a complex and essential process that allows organisms to grow, reproduce, and maintain their bodily functions. Disruptions in energy metabolism can lead to various diseases, including diabetes, obesity, and neurodegenerative disorders.

The postprandial period is the time frame following a meal, during which the body is engaged in the process of digestion, absorption, and assimilation of nutrients. In a medical context, this term generally refers to the few hours after eating when the body is responding to the ingested food, particularly in terms of changes in metabolism and insulin levels.

The postprandial period can be of specific interest in the study and management of conditions such as diabetes, where understanding how the body handles glucose during this time can inform treatment decisions and strategies for maintaining healthy blood sugar levels.

Body weight is the measure of the force exerted on a scale or balance by an object's mass, most commonly expressed in units such as pounds (lb) or kilograms (kg). In the context of medical definitions, body weight typically refers to an individual's total weight, which includes their skeletal muscle, fat, organs, and bodily fluids.

Healthcare professionals often use body weight as a basic indicator of overall health status, as it can provide insights into various aspects of a person's health, such as nutritional status, metabolic function, and risk factors for certain diseases. For example, being significantly underweight or overweight can increase the risk of developing conditions like malnutrition, diabetes, heart disease, and certain types of cancer.

It is important to note that body weight alone may not provide a complete picture of an individual's health, as it does not account for factors such as muscle mass, bone density, or body composition. Therefore, healthcare professionals often use additional measures, such as body mass index (BMI), waist circumference, and blood tests, to assess overall health status more comprehensively.

Obesity is a complex disease characterized by an excess accumulation of body fat to the extent that it negatively impacts health. It's typically defined using Body Mass Index (BMI), a measure calculated from a person's weight and height. A BMI of 30 or higher is indicative of obesity. However, it's important to note that while BMI can be a useful tool for identifying obesity in populations, it does not directly measure body fat and may not accurately reflect health status in individuals. Other factors such as waist circumference, blood pressure, cholesterol levels, and blood sugar levels should also be considered when assessing health risks associated with weight.

Food preferences are personal likes or dislikes towards certain types of food or drinks, which can be influenced by various factors such as cultural background, individual experiences, taste, texture, smell, appearance, and psychological factors. Food preferences can also be shaped by dietary habits, nutritional needs, health conditions, and medication requirements. They play a significant role in shaping an individual's dietary choices and overall eating behavior, which can have implications for their nutritional status, growth, development, and long-term health outcomes.

Cachexia is a complex metabolic disorder characterized by severe weight loss, muscle wasting, and weakness. It is often associated with chronic diseases such as cancer, HIV/AIDS, heart failure, kidney disease, and chronic obstructive pulmonary disease (COPD). Cachexia differs from simple malnutrition or starvation in that it involves a significant loss of muscle mass and an imbalance in energy metabolism, even when adequate calories are consumed.

The hallmark features of cachexia include:

1. Weight loss: Unintentional loss of more than 5% of body weight over 12 months or less, or more than 2% in individuals already underweight.
2. Muscle wasting: Reduction in skeletal muscle mass and strength, leading to weakness and functional impairment.
3. Fatigue and anorexia: Decreased appetite and reduced food intake due to various factors such as inflammation, hormonal imbalances, and psychological distress.
4. Inflammation: Elevated levels of pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6) that contribute to metabolic dysregulation and muscle wasting.
5. Insulin resistance: Impaired glucose uptake and utilization by cells, leading to increased blood glucose levels and altered energy metabolism.
6. Altered protein metabolism: Increased protein breakdown and decreased protein synthesis in skeletal muscles, contributing to muscle wasting.
7. Altered lipid metabolism: Increased lipolysis (breakdown of fat) and impaired lipogenesis (formation of fat), leading to loss of adipose tissue and altered energy storage.

Cachexia significantly impacts patients' quality of life, treatment outcomes, and overall survival. Currently, there is no single effective treatment for cachexia, and management typically involves addressing the underlying disease, nutritional support, exercise interventions, and pharmacological therapies to target specific aspects of the metabolic dysregulation associated with this condition.

Megestrol acetate is a synthetic progestin, which is a hormone that acts like progesterone in the body. It is used to treat various conditions such as endometrial cancer, breast cancer, and anorexia associated with AIDS. It works by blocking the action of certain hormones in the body, which can slow or stop the growth of some types of cancer cells. In addition, megestrol acetate can help increase appetite and weight gain in people with HIV/AIDS.

The medication is available in various forms, including tablets and oral suspension, and its use should be under the supervision of a healthcare professional who will determine the appropriate dosage based on the patient's medical condition and response to treatment. Common side effects of megestrol acetate include nausea, vomiting, diarrhea, gas, headache, dizziness, and changes in mood or sex drive.

Neuropeptide Y (NPY) is a neurotransmitter and neuropeptide that is widely distributed in the central and peripheral nervous systems. It is a member of the pancreatic polypeptide family, which includes peptide YY and pancreatic polypeptide. NPY plays important roles in various physiological functions such as energy balance, feeding behavior, stress response, anxiety, memory, and cardiovascular regulation. It is involved in the modulation of neurotransmitter release, synaptic plasticity, and neural development. NPY is synthesized from a larger precursor protein called prepro-NPY, which is post-translationally processed to generate the mature NPY peptide. The NPY system has been implicated in various pathological conditions such as obesity, depression, anxiety disorders, hypertension, and drug addiction.

Drinking behavior refers to the patterns and habits related to alcohol consumption. This can include the frequency, quantity, and context in which an individual chooses to drink alcohol. Drinking behaviors can vary widely among individuals and can be influenced by a variety of factors, including cultural norms, personal beliefs, mental health status, and genetic predisposition.

Problematic drinking behaviors can include heavy drinking, binge drinking, and alcohol use disorder (AUD), which is characterized by a pattern of alcohol use that involves problems controlling intake, being preoccupied with alcohol, continuing to use alcohol even when it causes problems, having to drink more to get the same effect, or having withdrawal symptoms when rapidly decreasing or stopping alcohol.

It's important to note that drinking behaviors can have significant impacts on an individual's health and well-being, as well as their relationships, work, and other aspects of their life. If you are concerned about your own drinking behavior or that of someone else, it is recommended to seek professional help from a healthcare provider or addiction specialist.

Phentermine is a defined in the medical field as a psychostimulant medication that is primarily used for short-term weight management. It acts as an appetite suppressant and has sympathomimetic properties, which means it stimulates the sympathetic nervous system, leading to increased heart rate and blood pressure.

Phentermine is available in various forms, including tablets, capsules, and orally disintegrating tablets. It is typically prescribed for individuals with a body mass index (BMI) of 30 or higher, or for those with a BMI of 27 or higher who have weight-related medical conditions such as high blood pressure, diabetes, or high cholesterol.

It's important to note that phentermine is intended for use in conjunction with a reduced-calorie diet and increased physical activity. It should not be used as a sole means of weight loss, and its long-term effectiveness and safety have not been established. Additionally, phentermine can be habit-forming and may cause dependence, so it should only be used under the close supervision of a healthcare provider.

Gastric emptying is the process by which the stomach empties its contents into the small intestine. In medical terms, it refers to the rate and amount of food that leaves the stomach and enters the duodenum, which is the first part of the small intestine. This process is regulated by several factors, including the volume and composition of the meal, hormonal signals, and neural mechanisms. Abnormalities in gastric emptying can lead to various gastrointestinal symptoms and disorders, such as gastroparesis, where the stomach's ability to empty food is delayed.

Intraventricular injections are a type of medical procedure where medication is administered directly into the cerebral ventricles of the brain. The cerebral ventricles are fluid-filled spaces within the brain that contain cerebrospinal fluid (CSF). This procedure is typically used to deliver drugs that target conditions affecting the central nervous system, such as infections or tumors.

Intraventricular injections are usually performed using a thin, hollow needle that is inserted through a small hole drilled into the skull. The medication is then injected directly into the ventricles, allowing it to circulate throughout the CSF and reach the brain tissue more efficiently than other routes of administration.

This type of injection is typically reserved for situations where other methods of drug delivery are not effective or feasible. It carries a higher risk of complications, such as bleeding, infection, or damage to surrounding tissues, compared to other routes of administration. Therefore, it is usually performed by trained medical professionals in a controlled clinical setting.

Agouti-related protein (AGRP) is a neuropeptide that functions as an endogenous antagonist of melanocortin receptors, specifically MC3R and MC4R. It is expressed in the hypothalamus and plays a crucial role in regulating energy balance, body weight, and glucose homeostasis. AGRP increases food intake and decreases energy expenditure by inhibiting melanocortin signaling in the hypothalamus. Dysregulation of AGRP has been implicated in various metabolic disorders, including obesity and type 2 diabetes.

In a medical context, taste is the sensation produced when a substance in the mouth reacts with taste buds, which are specialized sensory cells found primarily on the tongue. The tongue's surface contains papillae, which house the taste buds. These taste buds can identify five basic tastes: salty, sour, bitter, sweet, and umami (savory). Different areas of the tongue are more sensitive to certain tastes, but all taste buds can detect each of the five tastes, although not necessarily equally.

Taste is a crucial part of our sensory experience, helping us identify and differentiate between various types of food and drinks, and playing an essential role in appetite regulation and enjoyment of meals. Abnormalities in taste sensation can be associated with several medical conditions or side effects of certain medications.

Hyperphagia is a medical term that describes excessive eating or increased appetite, often to the point of compulsive overeating. It's more than just a simple increase in hunger or appetite; it's characterized by consuming large amounts of food beyond what is needed for normal growth and health.

This condition can be associated with several medical conditions. For instance, it's a common symptom in Prader-Willi syndrome, a genetic disorder that affects appetite, growth, and cognitive development. It can also occur in certain types of brain injuries or disorders affecting the hypothalamus, a part of the brain that regulates hunger and fullness signals.

However, it's important to note that hyperphagia should not be confused with binge eating disorder, another eating disorder characterized by consuming large amounts of food in a short period of time, but without the feeling of loss of control that is typical of binge eating.

As always, if you or someone else is experiencing symptoms of hyperphagia, it's important to seek medical advice to identify and treat any underlying conditions.

Dietary sodium is a mineral that is primarily found in table salt (sodium chloride) and many processed foods. It is an essential nutrient for human health, playing a crucial role in maintaining fluid balance, transmitting nerve impulses, and regulating muscle contractions. However, consuming too much dietary sodium can increase blood pressure and contribute to the development of hypertension, heart disease, stroke, and kidney problems.

The recommended daily intake of dietary sodium is less than 2,300 milligrams (mg) per day for most adults, but the American Heart Association recommends no more than 1,500 mg per day for optimal heart health. It's important to note that many processed and restaurant foods contain high levels of sodium, so it's essential to read food labels and choose fresh, whole foods whenever possible to help limit dietary sodium intake.

Furosemide is a loop diuretic medication that is primarily used to treat edema (fluid retention) associated with various medical conditions such as heart failure, liver cirrhosis, and kidney disease. It works by inhibiting the sodium-potassium-chloride cotransporter in the ascending loop of Henle in the kidneys, thereby promoting the excretion of water, sodium, and chloride ions. This increased urine output helps reduce fluid accumulation in the body and lower blood pressure.

Furosemide is also known by its brand names Lasix and Frusid. It can be administered orally or intravenously, depending on the patient's condition and the desired rate of diuresis. Common side effects include dehydration, electrolyte imbalances, hearing loss (in high doses), and increased blood sugar levels.

It is essential to monitor kidney function, electrolyte levels, and fluid balance while using furosemide to minimize potential adverse effects and ensure appropriate treatment.

Dexfenfluramine is a medication that was previously used as an appetite suppressant for weight loss. It is a stereoisomer (enantiomer) of fenfluramine, which is another appetite suppressant. Dexfenfluramine works by increasing the levels of serotonin in the brain, which helps to reduce appetite and promote weight loss.

However, dexfenfluramine was withdrawn from the market in 1997 due to concerns about its safety. Studies found that long-term use of dexfenfluramine was associated with an increased risk of primary pulmonary hypertension, a rare but serious condition that can lead to heart failure. Additionally, when dexfenfluramine was used in combination with phentermine (a different appetite suppressant), there was an increased risk of valvular heart disease.

Therefore, dexfenfluramine is no longer available for medical use and its prescription is not recommended due to these safety concerns.

Pro-opiomelanocortin (POMC) is a precursor protein that gets cleaved into several biologically active peptides in the body. These peptides include adrenocorticotropic hormone (ACTH), beta-lipotropin, and multiple opioid peptides such as beta-endorphin, met-enkephalin, and leu-enkephalin.

ACTH stimulates the release of cortisol from the adrenal gland, while beta-lipotropin has various metabolic functions. The opioid peptides derived from POMC have pain-relieving (analgesic) and rewarding effects in the brain. Dysregulation of the POMC system has been implicated in several medical conditions, including obesity, addiction, and certain types of hormone deficiencies.

A medical definition of 'food' would be:

"Substances consumed by living organisms, usually in the form of meals, which contain necessary nutrients such as carbohydrates, proteins, fats, vitamins, minerals, and water. These substances are broken down during digestion to provide energy, build and repair tissues, and regulate bodily functions."

It's important to note that while this is a medical definition, it also aligns with common understanding of what food is.

Phase IV clinical trials, also known as post-marketing surveillance trials or post-authorization studies, are research studies conducted after a drug or medical device has been approved for marketing and made available to the public. The primary objective of these trials is to gather additional information about the safety, efficacy, and optimal use of the product in larger and more diverse populations over a longer period of time than was possible during the initial phases of clinical development (Phases I-III).

Phase IV studies can be designed to:

1. Evaluate long-term safety and side effects: These trials monitor adverse events that may not have been detected in earlier, shorter-term studies, allowing researchers to identify rare or delayed reactions and assess the overall risk-benefit profile of the product in real-world settings.
2. Assess effectiveness in various patient populations: Phase IV trials can help determine how well a treatment works in specific groups, such as children, elderly individuals, or those with multiple medical conditions or taking other medications concurrently. This information can inform labeling changes and guide clinical decision-making.
3. Compare the product to alternative treatments: Head-to-head comparisons of different drugs or devices can help healthcare providers make evidence-based choices when selecting therapies for their patients.
4. Investigate new indications or uses: Phase IV trials may explore whether a drug or device is effective for treating additional conditions or in different dosages, formulations, or routes of administration.
5. Evaluate cost-effectiveness and value: These studies can help healthcare systems and payers understand the economic impact of a product, including its costs relative to its benefits and potential savings from improved health outcomes or reduced complications.

Phase IV clinical trials are essential for ensuring that new treatments continue to demonstrate safety and efficacy as they are used more widely in larger and more diverse populations. This information can lead to updates in labeling, guidelines, and prescribing practices, ultimately improving patient care and outcomes.

Weight loss is a reduction in body weight attributed to loss of fluid, fat, muscle, or bone mass. It can be intentional through dieting and exercise or unintentional due to illness or disease. Unintentional weight loss is often a cause for concern and should be evaluated by a healthcare professional to determine the underlying cause and develop an appropriate treatment plan. Rapid or significant weight loss can also have serious health consequences, so it's important to approach any weight loss plan in a healthy and sustainable way.

Blood glucose, also known as blood sugar, is the concentration of glucose in the blood. Glucose is a simple sugar that serves as the main source of energy for the body's cells. It is carried to each cell through the bloodstream and is absorbed into the cells with the help of insulin, a hormone produced by the pancreas.

The normal range for blood glucose levels in humans is typically between 70 and 130 milligrams per deciliter (mg/dL) when fasting, and less than 180 mg/dL after meals. Levels that are consistently higher than this may indicate diabetes or other metabolic disorders.

Blood glucose levels can be measured through a variety of methods, including fingerstick blood tests, continuous glucose monitoring systems, and laboratory tests. Regular monitoring of blood glucose levels is important for people with diabetes to help manage their condition and prevent complications.

Weight gain is defined as an increase in body weight over time, which can be attributed to various factors such as an increase in muscle mass, fat mass, or total body water. It is typically measured in terms of pounds or kilograms and can be intentional or unintentional. Unintentional weight gain may be a cause for concern if it's significant or accompanied by other symptoms, as it could indicate an underlying medical condition such as hypothyroidism, diabetes, or heart disease.

It is important to note that while body mass index (BMI) can be used as a general guideline for weight status, it does not differentiate between muscle mass and fat mass. Therefore, an increase in muscle mass through activities like strength training could result in a higher BMI, but this may not necessarily be indicative of increased health risks associated with excess body fat.

A melanocortin receptor (MCR) is a type of G protein-coupled receptor that binds melanocortin peptides. The melanocortin system plays crucial roles in various biological processes such as pigmentation, energy homeostasis, sexual function, and inflammation.

The melanocortin receptor 4 (MC4R) is one of the five subtypes of MCRs, which is widely expressed in the central nervous system, including the hypothalamus, and some peripheral tissues. MC4R is a key component in the regulation of energy balance, appetite, and body weight. Activation of MC4R by melanocortin peptides, such as α-melanocyte stimulating hormone (α-MSH), leads to decreased food intake and increased energy expenditure, while antagonism or deficiency of MC4R results in obesity.

In summary, the medical definition of 'Receptor, Melanocortin, Type 4' is a G protein-coupled receptor that binds melanocortin peptides and plays a critical role in regulating energy balance, appetite, and body weight.

Dietary carbohydrates refer to the organic compounds in food that are primarily composed of carbon, hydrogen, and oxygen atoms, with a general formula of Cm(H2O)n. They are one of the three main macronutrients, along with proteins and fats, that provide energy to the body.

Carbohydrates can be classified into two main categories: simple carbohydrates (also known as simple sugars) and complex carbohydrates (also known as polysaccharides).

Simple carbohydrates are made up of one or two sugar molecules, such as glucose, fructose, and lactose. They are quickly absorbed by the body and provide a rapid source of energy. Simple carbohydrates are found in foods such as fruits, vegetables, dairy products, and sweeteners like table sugar, honey, and maple syrup.

Complex carbohydrates, on the other hand, are made up of long chains of sugar molecules that take longer to break down and absorb. They provide a more sustained source of energy and are found in foods such as whole grains, legumes, starchy vegetables, and nuts.

It is recommended that adults consume between 45-65% of their daily caloric intake from carbohydrates, with a focus on complex carbohydrates and limiting added sugars.

Ghrelin receptors are a type of G protein-coupled receptor found in the central nervous system and other tissues throughout the body. They are also known as growth hormone secretagogue receptor 1a (GHS-R1a) because they were initially identified as being activated by synthetic ligands called growth hormone secretagogues, which stimulate the release of growth hormone.

However, it was later discovered that ghrelin, a hormone produced in the stomach, is the natural endogenous ligand for these receptors. Ghrelin is often referred to as the "hunger hormone" because its levels rise before meals and decrease after eating, signaling to the brain that it's time to eat.

Activation of ghrelin receptors has been shown to have a variety of effects on the body, including stimulating appetite, increasing growth hormone secretion, promoting fat storage, and modulating glucose metabolism. Dysregulation of the ghrelin system has been implicated in various pathological conditions such as obesity, anorexia nervosa, and type 2 diabetes.

The pylorus is the lower, narrow part of the stomach that connects to the first part of the small intestine (duodenum). It consists of the pyloric canal, which is a short muscular tube, and the pyloric sphincter, a circular muscle that controls the passage of food from the stomach into the duodenum. The pylorus regulates the entry of chyme (partially digested food) into the small intestine by adjusting the size and frequency of the muscular contractions that push the chyme through the pyloric sphincter. This process helps in further digestion and absorption of nutrients in the small intestine.

Insulin is a hormone produced by the beta cells of the pancreatic islets, primarily in response to elevated levels of glucose in the circulating blood. It plays a crucial role in regulating blood glucose levels and facilitating the uptake and utilization of glucose by peripheral tissues, such as muscle and adipose tissue, for energy production and storage. Insulin also inhibits glucose production in the liver and promotes the storage of excess glucose as glycogen or triglycerides.

Deficiency in insulin secretion or action leads to impaired glucose regulation and can result in conditions such as diabetes mellitus, characterized by chronic hyperglycemia and associated complications. Exogenous insulin is used as a replacement therapy in individuals with diabetes to help manage their blood glucose levels and prevent long-term complications.

Eating disorders are mental health conditions characterized by significant disturbances in eating behaviors and associated distressing thoughts and emotions. They include several types of disorders, such as anorexia nervosa, bulimia nervosa, binge eating disorder, and other specified feeding or eating disorders (OSFED). These disorders can have serious medical and psychological consequences if left untreated.

Anorexia nervosa is characterized by restrictive eating, low body weight, and an intense fear of gaining weight or becoming fat. Individuals with anorexia may also have a distorted body image and deny the severity of their low body weight.

Bulimia nervosa involves recurrent episodes of binge eating followed by compensatory behaviors such as purging (e.g., self-induced vomiting, misuse of laxatives or diuretics), fasting, or excessive exercise to prevent weight gain.

Binge eating disorder is characterized by recurrent episodes of eating large amounts of food in a short period of time, often to the point of discomfort, accompanied by feelings of loss of control and distress. Unlike bulimia nervosa, individuals with binge eating disorder do not engage in compensatory behaviors to prevent weight gain.

Other specified feeding or eating disorders (OSFED) include atypical anorexia nervosa, subthreshold bulimia nervosa, and subthreshold binge eating disorder, which may have similar symptoms to the above disorders but do not meet all the diagnostic criteria.

Eating disorders can affect people of any age, gender, race, or ethnicity, and they are often associated with other mental health conditions such as depression, anxiety, and obsessive-compulsive disorder. Treatment typically involves a combination of psychological therapy, nutrition counseling, and medical management to address both the physical and psychological aspects of the disorder.

Nutritional status is a concept that refers to the condition of an individual in relation to their nutrient intake, absorption, metabolism, and excretion. It encompasses various aspects such as body weight, muscle mass, fat distribution, presence of any deficiencies or excesses of specific nutrients, and overall health status.

A comprehensive assessment of nutritional status typically includes a review of dietary intake, anthropometric measurements (such as height, weight, waist circumference, blood pressure), laboratory tests (such as serum albumin, total protein, cholesterol levels, vitamin and mineral levels), and clinical evaluation for signs of malnutrition or overnutrition.

Malnutrition can result from inadequate intake or absorption of nutrients, increased nutrient requirements due to illness or injury, or excessive loss of nutrients due to medical conditions. On the other hand, overnutrition can lead to obesity and related health problems such as diabetes, cardiovascular disease, and certain types of cancer.

Therefore, maintaining a good nutritional status is essential for overall health and well-being, and it is an important consideration in the prevention, diagnosis, and treatment of various medical conditions.

Wikiquote has quotations related to Appetite. Look up appetite in Wiktionary, the free dictionary. Specific appetite Orexigenic ... Appetite is the desire to eat food items, usually due to hunger. Appealing foods can stimulate appetite even when hunger is ... Mechanisms controlling appetite are a potential target for weight loss drugs. Appetite control mechanisms seem to strongly ... Taste and smell ("dysgeusia", bad taste) or the lack thereof may also effect appetite. Abnormal appetite may also be linked to ...
... is a 2010 novel by Janet Evanovich set in Salem, Massachusetts. Elizabeth Tucker (referred to as Lizzie) is a ... "Wicked Appetite - Janet Evanovich, #1 NYT Bestselling Author". "Wicked Business Cover , Janet Evanovich". www.evanovich.com. ...
An orexigenic, or appetite stimulant, is a drug, hormone, or compound that increases appetite and may induce hyperphagia. This ... Agents Used as Appetite Stimulants: Drug Class; University of Utah College of Pharmacy, 2014 Media related to Appetite ... Usually appetite enhancement is considered an undesirable side effect of certain drugs as it leads to unwanted weight gain, but ... Caton SJ, Nolan LJ, Hetherington MM (2015). "Alcohol, Appetite and Loss of Restraint". Curr Obes Rep. 4 (1): 99-105. doi: ...
Other appetites are thus currently classified as learned appetites, which are not innate appetites that are triggered ... An example of an unlearned appetite might be caloric appetite, as seen in all domestic animals. Other unlearned appetites are ... Specific appetite is one such mechanism. Specific appetite has been demonstrated in various species for a number of vitamins ... Appetite, 1999; 32(2): 251-260 Kochli, Tenenbaum-Rakover, Leshem. Increased salt appetite in patients with CAH-21-OH deficiency ...
Polish Unit Production Management Appetite Production official website (in English and Polish) Appetite Production listed by ... Appetite Production is a Polish film production company, based in Krakow, Poland. The company was founded in 2008 by Joanna ... Appetite's first production was an independent live action short comedy Merry Christmas with Jason Nwoga and directed by Tomasz ... Appetite Production at Short Film Corner Cannes 2009 (in French) Joanna Szymanska in Polish Film Database (in Polish) ...
Appetite is the desire for nourishment. Appetite may also refer to: Appetite (album), an album by Kris Delmhorst "Appetite" ( ... "Appetite", a 2008 song by Usher from the album Here I Stand Appetite (art gallery), a former Argentinian art gallery Appetite ( ... Look up appetite in Wiktionary, the free dictionary. ... a Polish film production company Specific appetite, a drive to ... This disambiguation page lists articles associated with the title Appetite. If an internal link led you here, you may wish to ...
"Source details: Appetite". Scopus preview. Elsevier. Retrieved 2019-05-03. "Appetite". 2018 Journal Citation Reports. Web of ... Appetite is a monthly peer-reviewed scientific journal covering research on normal and disordered eating and drinking in ... "Appetite". MIAR: Information Matrix for the Analysis of Journals. University of Barcelona. Retrieved 2019-05-03. "Embase ... "Appetite". NLM Catalog. National Center for Biotechnology Information. Retrieved 2019-05-03. "PsycINFO Journal Coverage". ...
... also began recording new material in July, with hopes of releasing it by the end of 2009. Adler's Appetite ... Adler's Appetite (CD inlay). Adler's Appetite. Arrogant Bastard Ltd. 2005.{{cite AV media notes}}: CS1 maint: others in cite AV ... For 20th Anniversary of Appetite For Destruction, Adler's Appetite performed a show at the Key Club in Hollywood where they ... The following month, they renamed the band Adler's Appetite, after Adler and the Appetite for Destruction album that they ...
Appetite is the debut album by singer/songwriter Kris Delmhorst, released in 1998. All songs by Kris Delmhorst. "Sleeping Dogs ... Thomas Hoebbel and Charan Devereaux Official Kris Delmhorst website Appetite at AllMusic (Articles with short description, ...
... with an overarching risk appetite framework to ensure consistency. Precise measurement is not always possible and risk appetite ... Risk appetite is the level of risk that an organization is prepared to accept in pursuit of its objectives, before action is ... The "appetite" follows logically from this analysis. For example, an organization should be "hungry for risk" if it has more ... Below are examples of broad approaches to setting risk appetite that a business may adopt to ensure a response to risk that is ...
... is the debut studio album by the German IDM duo Funkstörung. It was released on Studio !K7 on April ... In the next year, the duo released the debut studio album, Appetite for Disctruction, on Studio !K7. Five years in the making, ... Appetite for Disctruction at Discogs (list of releases) (Articles with short description, Short description is different from ... "Appetite for Disctruction - Funkstörung". AllMusic. Retrieved November 14, 2014. "Must Hear". CMJ New Music Report: 28. May 1, ...
Appetite (stylized as APPETITE) was a gallery and artist-run space, founded by Daniela Luna, in the neighborhood of San Telmo, ... APPETITE participation at this fair was noticed by the New York Times as well: "Appetite gallery will get additional exposure ... And when a booth is crowded, the pieces can be blamed, as is the case at Appetite, a gallery with branches in Buenos Aires and ... A cultural site, Leedor, writes of it: "Appetite and Tanto Deseo, two galleries with young spirit, that intent to give a space ...
... at YouTube (streamed copy where licensed) Appetite for Destruction at Acclaimed Music (list of ... Appetite for Destruction is the debut studio album by American hard rock band Guns N' Roses, released by Geffen Records on July ... Enter Appetite For Destruction in the "Artiest of titel" box. Select 1996 in the drop-down menu saying "Alle jaargangen". "New ... "Appetite for Destruction: Super Deluxe Edition [Box Set] by Guns N' Roses". Metacritic. Archived from the original on July 9, ...
"Groovie Ghoulies - Appetite For Adrenochrome [Reissue]". www.punknews.org. "Groovie Ghoulies: Appetite For Adrenochrome". Music ... Appetite for Adrenochrome is the debut album by the Sacramento punk rock band the Groovie Ghoulies. It was released in 1989 on ... Appetite for Adrenochrome was remastered and reissued by Lookout! Records in September 1996. This version was re-released by ... A cover of Kiss' 1976 top-ten hit "Beth" appears as an unlisted track at the end of Appetite for Adrenochrome. The Groovie ...
... is an album by Some Velvet Sidewalk. It was released in 1990. Trouser Press wrote that "between the ... "Appetite for Extinction - Some Velvet Sidewalk , Reviews , AllMusic" - via www.allmusic.com. "Some Velvet Sidewalk , Biography ...
Unlike Adler's Appetite's first EP, all the tracks on Alive are completely written by Adler's Appetite and Fred Coury, and ... "adler's appetite alive picture - Google Search". www.google.ca. Retrieved 2017-02-12. bravewords.com. "ADLER'S APPETITE - Alive ... "ADLER'S APPETITE Rehearsing With ACES 'N' EIGHTS Singer". BLABBERMOUTH.NET. 2011-04-18. Retrieved 2017-02-11. "Adler's Appetite ... "Adler's Appetite LIVE! , hardrockhaven.net". hardrockhaven.net. Retrieved 2017-02-11. "Adler's Appetite , Hard Rock Hideout". ...
"Guns N' Roses - Appetite For Democracy 3D Review • metal.de". "'Appetite for Democracy' Deluxe Edition Available Nov. 4". ... "Guns N' Roses announce new concert film, Appetite for Democracy 3D". May 29, 2014. "GUNS N' ROSES: 'Appetite For Democracy 3D: ... "antiMusic.com: Guns N' Roses - Appetite for Democracy 3D Review". www.antimusic.com. "Guns N' Roses - Appetite For Democracy: ... as part of the Appetite for Democracy tour in celebration of twenty-five years of Appetite for Destruction and four years of ...
Appetite for Destruction is a 1987 album by Guns N' Roses. Appetite for Destruction may also refer to: Appetite for Destruction ... "Appetite for Destruction", an episode of The Loud House Appetite for Disctruction, a 2000 album by Funkstörung This ... Appetite for Destruction, a painting by Robert Williams Appetite for Destruction, a professional wrestling tag team consisting ... Ruby Isle album) (2010) "Appetite for Destruction" (song), a 1991 song by N.W.A. ...
Appetite for Democracy was a series of concerts by hard rock band Guns N' Roses celebrating 25 years of Appetite for ... "Guns N' Roses: Appetite for Democracy". The Joint, Las Vegas. Archived from the original on November 22, 2012. Retrieved August ... "Guns N' Roses To Launch Appetite for Democracy On Halloween". Anti Music. August 14, 2012. Retrieved August 17, 2012. "Guns N' ... Roses brings Appetite for Democracy to Las Vegas". Ticket News. August 17, 2012. Retrieved August 17, 2012. "Guns N' Roses ...
"Appetite" at MusicBrainz (list of releases) "Appetite" at Discogs (Articles with short description, Short description matches ... "Appetite" (アペタイト, Apetaito) is the 34th single by Japanese entertainer Akina Nakamori. Written by Seriko Natsuno and U-ki, the ... "APPETITE , 中森明菜". Oricon. Retrieved 2022-08-24. "中森明菜". Yamachan Land. Archived from the original on 2011-05-24. Retrieved 2022 ...
"Appetite" Side 2 "Heaven Can Wait (Instrumental version of 'When The Angels')" Side 1 "Appetite" Side 2 "Heaven Can Wait ( ... Paddy McAloon wrote "Appetite' in 1984. It was one of the first songs he had composed on a keyboard and was written using a " ... "Appetite" is a song by English pop band Prefab Sprout from their album Steve McQueen. Released as the album's third single by ... "Appetite" has received critical acclaim, with many considering it a highlight of Steve McQueen. In 1986, Ian Pye of Abbey ...
"Appetite for Destruction" is a song by American hip hop group N.W.A. The song is the second single from their final studio ... "Number 10 is my appetite to kill". An extended version of the song for the music video also appeared on the home video ...
The Appetite for Destruction Tour, by American hard rock band Guns N' Roses, promoted their debut album Appetite for ... " "Paradise City" Classic "Appetite for Destruction" line-up Axl Rose - lead vocals Slash - lead guitar Izzy Stradlin - rhythm ...
... : The Making of a Scientist is the first volume of the autobiographical memoir by British evolutionary ... Marek Kohn, The Independent - "Book review: An Appetite for Wonder: The Making of a Scientist, By Richard Dawkins", 27 ... p27 Leah Libresco Sargeant: "Incurious Dawkins A review of Richard Dawkins' memoir, An Appetite for Wonder.", March 2014, at ... Brandon Robshaw, "Book review: An Appetite For Wonder, by Richard Dawkins. An insight beyond the caricature", The Independent, ...
... was a three-month 2007 concert tour that was co-headlined by rock bands Switchfoot and ... The tour's name is a reference to "Appetite for Destruction", the debut album of American hard rock band Guns N' Roses. Ruth ...
Official website Healthy Appetite with Ellie Krieger at IMDb v t e v t e (Webarchive template wayback links, Articles with ... Healthy Appetite with Ellie Krieger is a television series on Food Network airing since 2006 and hosted by Ellie Krieger. "Food ...
... is a jazz album by Carla Bley released in 1974, following her debut Escalator over the Hill. The lyrics are ... ECM/WATT discography accessed August 25, 2016 Tropic Appetites at AllMusic (Articles with short description, Short description ... vocals Tropic Appetites at AllMusic Swenson, J., ed. (1985). The Rolling Stone Jazz Record Guide. USA: Random House/Rolling ...
Appetite for Destruction is a 2010 album by Ruby Isle. It is a cover of Guns N' Roses' 1987 album of the same name. It was ...
"Adler's Appetite Singer Quits". Blabbermouth.net. April 13, 2009. Retrieved February 6, 2019. "Adler's Appetite Joined By ... "Adler's Appetite: Two New Songs Released". Blabbermouth.net. December 27, 2010. Retrieved February 6, 2019. "Adler's Appetite ... "Adler's Appetite: West Coast Dates Announced". Blabbermouth.net. August 18, 2003. Retrieved February 6, 2019. "Adler's Appetite ... "Adler's Appetite: New Lineup Confirmed". Blabbermouth.net. December 21, 2005. Retrieved February 6, 2019. "The Adler's Appetite ...
... is a 2013 memoir by Kate Christensen from when she was a girl growing up ... "Blue plate special: an autobiography of my appetites: Reviews". catalog.wccls.org. Retrieved February 9, 2017. Pitched to fans ... "Blue plate special : an autobiography of my appetites". Buffalo and Erie County Public Library. Retrieved February 9, 2017. ... "Blue Plate Special: An Autobiography of My Appetites". Publishers Weekly. PWxyz LLC. June 10, 2013. Retrieved February 9, 2017 ...
Metformin-induced hepatokine reduces appetite Shimona Starling. Nat Rev Endocrinol. 2020 Mar. ... The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an ... Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat. Metab. 1, 1202-1208 ...
Wikiquote has quotations related to Appetite. Look up appetite in Wiktionary, the free dictionary. Specific appetite Orexigenic ... Appetite is the desire to eat food items, usually due to hunger. Appealing foods can stimulate appetite even when hunger is ... Mechanisms controlling appetite are a potential target for weight loss drugs. Appetite control mechanisms seem to strongly ... Taste and smell ("dysgeusia", bad taste) or the lack thereof may also effect appetite. Abnormal appetite may also be linked to ...
This review highlights the key areas of research in the hypothalamic control of appetite. ... Although ghrelin has potent actions on appetite, ghrelin-null mice and ghrelin receptor-knockout mice have normal appetite and ... Multiple neuropeptides have been identified that appear to modulate pathways within the hypothalamus to control appetite.. ... PP stimulates appetite and increases hypothalamic NPY expression.[205] These contrasting effects of PP on feeding depending on ...
Increased appetite means you have an excess desire for food. ... Increased appetite means you have an excess desire for food. ... An increased appetite can be a symptom of different diseases. For example, it may be due to a mental condition or a problem ... An increased appetite can come and go (intermittent), or it can last for long periods of time (persistent). This will depend on ... If a medicine is causing increased appetite and weight gain, your health care provider may decrease your dose or have you try ...
I had been on Remeron for depression and it had helped my appetite. I am off it now, and have n... ... Is anyone taking any drugs to stimulate your appetite? ... I am off it now, and have noticed that my appetite has gone ... Is anyone taking any drugs to stimulate your appetite? I had been on Remeron for depression and it had helped my appetite. I am ... Is anyone taking any drugs to stimulate your appetite? I had been on Remeron for depression and it had helped my appetite. ...
... how artificial sweeteners can stimulate appetite in the brain. Billions of people worldwide consume artificial sweeteners and ... Why artificial sweeteners can increase appetite. Date:. July 12, 2016. Source:. University of Sydney. Summary:. Researchers ... "Why artificial sweeteners can increase appetite." ScienceDaily. www.sciencedaily.com. /. releases. /. 2016. /. 07. /. ... This is the first study to identify how artificial sweeteners can stimulate appetite, with researchers identifying a complex ...
Researchers discover a neural circuit that controls appetite in mice. Switching it off or on causes full mice to eat as if ... Appetite-regulating neural pathway identified. Research Update April 27, 2015. A team including NIDDK researchers discovered a ... A neural basis for melanocortin-4 receptor regulated appetite. Nature Neuroscience. 2015;18(6):863-871. ... neural circuit that controls appetite in the brains of mice. Using a wide array of multidisciplinary techniques, the team found ...
The trick is in how to do this without starving! - Appetite Control Tips - Low Carb at BellaOnline ... Slow Music Slows your Appetite Research. Eat Slowly = Realize Youre Full. Your stomach doesnt communicate instantly with your ...
The dollar gained as appetite for risk dwindled in London early on Thursday, as markets waited for U.S. jobs data and updates ... Risk appetite had grown on Wednesday after ISM data in the United States new service industry orders jumped to a record high. ... LONDON, Aug 6 (Reuters) - The dollar gained as appetite for risk dwindled in London early on Thursday, as markets waited for U. ...
... Angela Macdonald-SmithSenior resources writer ... which has already voiced appetite to buy power from the project. ...
No Appetite for Bullying will include a teen coalition to bring together students between the ages of 13 and 17 to share ... Kids with Food Allergies (KFA)- the food allergy division of AAFA-is proud to support No Appetite for Bullying, a campaign to ... To bring attention to this issue and promote greater acceptance of those living with food allergies, KFA joins the No Appetite ...
... or feel full after eating only a small amount.Ongoing appetite loss may lead to serious complications. These include weight ... Appetite loss or poor appetite are common side effects from cancer and its treatment. This means that you may eat less than ... Causes of appetite loss. Many different things can cause appetite loss in a person with cancer:. * Changes in metabolism, which ... Appetite loss or poor appetite are common side effects from cancer and its treatment. This means that you may eat less than ...
Interviews with multiple House Republicans from the Midwest and Northeast reveal almost zero appetite to vote on any sort of ...
You have to enable JavaScript in your browsers settings in order to use the eReader.. Or try downloading the content offline. DOWNLOAD ...
Stress is prevalent in modern society and can affect human health through its effects on appetite. However, knowledge about the ... Neural effects of acute stress on appetite: a magnetoencephalography study Peer-Reviewed Publication Osaka City University ... Subjective levels of stress and appetite were then assessed using a visual analog scale. Electrocardiography was performed to ... Neural effects of acute stress on appetite: a magnetoencephalography study. Osaka City University ...
Find the best of Healthy Appetite with Ellie Krieger from Food Network ...
Majority of the time is due to heartburn, and others its due to me not having an appetite at… ... Im 30 weeks and have been feeling very full lately! I havent had this before but my appetite has gone down! I know we need to ... Majority of the time is due to heartburn, and others its due to me not having an appetite at all. At the growth appointment my ...
Cancer and its treatment can have effects that cause a loss of appetite and change in eating habits. Learn more here. ... Loss of appetite is called anorexia. People with a very low appetite that lasts more than a few days usually lose weight. ... A person who has anorexia (poor appetite or no appetite) may eat much less than normal or may not eat at all. This is common ... What causes loss of appetite?. People with cancer might have many factors that affect their appetite, most commonly its the ...
... to whet your appetite. Whet means to hone or to make more keen or stimulated, whereas wet means to cover or soak with ... Is appetite a noun?. Yes, the word appetite is a noun; a word for the desire for food or drink; the desire or inclination for ... What blues song has lyric you wet my appetite?. The song is called WHET my appetite, sung by Teresa James! ... How do you whet appetite?. You whet an appetite by smelling or tasting something that you really like. ...
Still recovering from the ravages of war, Bosnians have no shortage of anxiety, what with growing unemployment and poverty. This has sparked a rise in depression, and with it, a rise in the use of tranquilizers and antidepressants.
APPETITE AND WEIGHT WITH P.H.A.T. adrenalinum, adrenocorticotrophin, agrimonia eupatoria, flos, anacardium orientale, ... APPETITE AND WEIGHT WITH P.H.A.T.- adrenalinum, adrenocorticotrophin, agrimonia eupatoria, flos, anacardium orientale, ... Adrenalinum ................................increased appetite, indigestion. Adrenocorticotrophin (30X) ............. fat face ... Oleander .....................................hurried eating without appetite. Pituitarum posterium ...
Asian markets are set to open higher on Thursday, lifted by Wall Streets surge the day before as investors dovish interpretation of Fed chief Jerome Powells post-meeting press conference pushed U.S. Treasury yields to a two-week low. The Asian and Pacific economic calendar on Thursday is light on quantity but fairly heavy on significance - South Korean inflation and Australian trade are the main indicators, while the policy highlight is the Malaysian central banks interest rate decision.
Here is Photos For Appetite (26 pics) entry added to the daily Pics section on Acidcow.com ...
Appetite in China still strong: Coca-Cola. By Dai Tian (China Daily) Updated: 2015-09-12 14:22 ... "We continue to be excited about the growth opportunities in China, so the new normal has not reduced by any means our appetite ...
... Neuroscience. 2017 Dec 16:366:54-61. doi: ...
Todays episode is about how investors in the secondary market are reacting to rapid rate changes and which non-QM lenders are expanding.
Pharmacological Actions : Appetite Depressants : CK(42) : AC(9). Additional Keywords : Appetite Depressants, chocolate, ...
Patrick Hart of Gethsemani Abbey regarding Zen and the Birds of Appetite. Index item 1.. «I am delighted to enclose fully ... Contract with Editora Vozes in Brazil for a Portuguese language edition of Zen and the Birds of Appetite. Index item 2.. « ... Contract with Aldo Garzanti in Italy for an Italian language edition of Zen and the Birds of Appetite. Index item 3.. « ... Contract with New Directions Publishing Corporation in the United States for Zen and the Birds of Appetite. Index item 1.. « ...

No FAQ available that match "appetite"

No images available that match "appetite"